“Alnylam’s Knockout Move: How Amvuttra Just Changed the Game in ATTR-CM”
The FDA on Thursday approved Alnylam’s RNAi therapeutic a few days ahead of schedule, giving Amvuttra (vutrisiran) a green light to treat transthyretin-mediated amyloid cardiomyopathy […]